TNF and inflammatory bowel disease: A recent study done by Roblin et al., showed that combination therapy can result in better clinical outcomes without clinical failure or unfavorable pharmacokinetics at 24 months in patients with IBD who experienced an immune-mediated loss of response with first anti-TNF (13).